MCIA aims to develop credible, legitimate and reviewed resources that will support and assist patient groups, medical practitioners and health professionals, and researchers.
The links below provide access to education materials developed by TGA to assist the industry to understand the requirements in relation to advertising related to medicinal cannabis.
Resources for Industry
The Australian medicinal cannabis has grown rapidly since its inception in 2016 and is now seeking to grow its export capability, with a focus on developing the frameworks and capability needed to navigate the new regulatory environment…
Medicinal Cannabis Industry Australia (MCIA) has released a roadmap that outlines opportunities for the sector and strategic levers that need to be addressed to enable the sector to capitalise on these opportunities.
Developed by MTPConnect in partnership with Deloitte Access Economics, MCIA was pleased to initiate consultation with MTPConnect to develop this evidence based report for the industry and we thank MTPConnect for their support and work in developing this resource.
The Report provides an evidence base for the current and future medicinal cannabis industry in Australia and is a valuable resource for policymakers, industry and consumers.
The Therapeutic Goods Administration (TGA) is reminding businesses involved with medicinal cannabis products of their regulatory obligations under the Therapeutic Goods Act 1989 (the Act). Regulatory controls on medicinal cannabis minimise the risk of harm from inappropriate use while ensuring that product is available to patients where appropriate. The amount of regulatory control needed to manage risks depends on the product and determines how consumers access the product.
Resources for Consumers
The Therapeutic Goods Administration (TGA) is warning consumers about the risks of buying medicinal cannabis products online. Medicinal cannabis products bought online may be unsafe, of poor quality or contain a different dose to what the label claims.